These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 28685537

  • 1. Effect of Xianling Gubao capsules on bone mineral density in osteoporosis patients.
    Wu ZH, Zhu X, Xu CK, Chen YJ, Zhang L, Zhang CL.
    J Biol Regul Homeost Agents; 2017; 31(2):359-363. PubMed ID: 28685537
    [Abstract] [Full Text] [Related]

  • 2. [Effects of Xianling Gubao capsules for the treatment of bone loss induced by glucocorticoid].
    Wu JJ, Wen LP, Wu YG, Shen Q, Han Y.
    Zhongguo Gu Shang; 2009 Mar; 22(3):193-5. PubMed ID: 19366101
    [Abstract] [Full Text] [Related]

  • 3. [Systemic evaluation and Meta-analysis of Xianling Gubao capsule in treatment of primary osteoporosis in randomized controlled trials].
    Wang GQ, Liao X, Zhang YL, Xie YM.
    Zhongguo Zhong Yao Za Zhi; 2017 Aug; 42(15):2829-2844. PubMed ID: 29139246
    [Abstract] [Full Text] [Related]

  • 4. [Effect of Xianling Gubao capsule on bone metabolism in ovariectomized rats].
    Xi HR, Wang YY, Yang FF, Li WY, Ma HP, Chen KM.
    Zhongguo Zhong Yao Za Zhi; 2018 Jul; 43(13):2751-2757. PubMed ID: 30111027
    [Abstract] [Full Text] [Related]

  • 5. [Investigation of bone mineral density and serum type I collagen C-telopeptide in 653 female adults in Zhuhai area].
    Wang JJ, Zhang XR, Li XD.
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jul; 30(7):1612-4. PubMed ID: 20650781
    [Abstract] [Full Text] [Related]

  • 6. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y, Jamart J, Esselinckx W, Devogelaer JP.
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [Abstract] [Full Text] [Related]

  • 7. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 8. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 9. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
    Loddenkemper K, Bohl N, Perka C, Burmester GR, Buttgereit F.
    Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
    [Abstract] [Full Text] [Related]

  • 10. Effects of different extracts of kanggushu on osteoporosis in model rats and the underlying mechanisms.
    Gao ZM, Yang L, Huang F, Xiong AH, Zhou N, Zhou L, Li KY, Deng JL, Li KY, Liu W, Chen Y, Luo WT, Nie H.
    Chin J Integr Med; 2013 Nov; 19(11):844-52. PubMed ID: 23090360
    [Abstract] [Full Text] [Related]

  • 11. Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients.
    Wang SX, Li H.
    Chin Med J (Engl); 2008 Jul 20; 121(14):1280-4. PubMed ID: 18713548
    [Abstract] [Full Text] [Related]

  • 12. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K, Brandsaeter B, Wiencke K, Bjøro T, Godang K, Bollerslev J, Schrumpf E.
    Scand J Gastroenterol; 2003 Mar 20; 38(3):320-7. PubMed ID: 12737449
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The relationship between the metabolic syndrome and its components and bone status in postmenopausal women.
    Fodor D, Vesa S, Albu A, Simon S, Craciun A, Muntean L.
    Acta Physiol Hung; 2014 Jun 20; 101(2):216-27. PubMed ID: 24901081
    [Abstract] [Full Text] [Related]

  • 15. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
    Rey D, Treger M, Sibilia J, Priester M, Bernard-Henry C, Cheneau C, Javier RM.
    Infect Dis (Lond); 2015 Feb 20; 47(2):88-95. PubMed ID: 25426996
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 20; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 18. Comparative Efficacy of Xianling Gubao Capsules in Improving Bone Mineral Density in Postmenopausal Osteoporosis: A Network Meta-Analysis.
    Luo MH, Zhao JL, Xu NJ, Xiao X, Feng WX, Li ZP, Zeng LF.
    Front Endocrinol (Lausanne); 2022 Feb 20; 13():839885. PubMed ID: 35250888
    [Abstract] [Full Text] [Related]

  • 19. [Prevention and treatment of aromatase inhibitor-associated bone loss by shugan jiangu recipe in postmenopausal women with breast cancer: a clinical study].
    Li YQ, Sun H, Xue D, Xu YC, Li ZD, Wang W, Li PP.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep 20; 34(9):1064-8. PubMed ID: 25335329
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.